Download Files:
Products Details
Product Description
– Rifaquizinone (CBR-2092) is a Rifamycin-Quinolone Hybrid Antibiotic. Rifaquizinone inhibits wild-type S. aureus RNA polymerase with an IC50 of 34 nM. Rifaquizinone is effective against S. aureus infections, with MICs ranged from 0.008 to 0.5 μg/mL for 300 clinical isolates of staphylococci and streptococci[1][2].
Web ID
– HY-135184
Shipping
– Room temperature
Molecular Formula
– C65H81FN6O15
References
– [1]Robertson GT, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother. 2008 Jul;52(7):2313-23.|[2]Robertson GT, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. Antimicrob Agents Chemother. 2008 Jul;52(7):2324-34.
CAS Number
– 922717-97-3
Molecular Weight
– 1205.37
SMILES
– CN(C1CCN(CC1)/N=C/C2=C3C(O)=C4C(C5=C(O[C@@](C5=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(C(N3)=O)/C)C)O)C)O)C)OC(C)=O)C)OC)C)C(C)=C4O)=C2O)C6([C@@]7([H])CN(C8=C(C9=C(C%10CC%10)C=C(C(N9C=C8F)=O)C(O)=O)C)CC7)CC6
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– 10 mM in DMSO
Target
– Antibiotic;Bacterial;DNA/RNA Synthesis
Pathway
– Anti-infection;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
